When to suspect infantile hypercalcemia-1?
25(OH)D3
25(OH)D3/24,25(OH)2D3
Idiopathic infantile hypercalcemia
Nephrocalcinosis
Nephrolithiasis
Vitamin D
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
08 Feb 2024
08 Feb 2024
Historique:
received:
05
11
2023
accepted:
11
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
aheadofprint
Résumé
The screening test to suspect infantile hypercalcemia-1 (HCINF1) is the measure of 25(OH)D We compared the levels of total serum calcium and PTH of 6 patients with HCINF1 harboring biallelic CYP24A1 pathogenic variants with 3 different control groups: (1) 12 subjects wild type for CYP24A1; (2) 12 subjects matched for age and sex; (3) 12 subjects matched for vitamin D levels. We validated the cut-offs, testing the number of adult patients affected by HCINF1 reported in the literature that could be identified using these cut-offs. A serum calcium level > 9.6 mg/dL showed the highest sensitivity (100%) and specificity (91%) in the comparison between homozygous and wild-type subjects. A serum PTH index < 0.315 showed the highest sensitivity (100%) and specificity (83.3%). A serum calcium level > 9.6 mg/dL was able to identify all adult HCINF1 patients whereas a PTH ratio < 0.315 identified 89.8% of the cases. Superimposable results were obtained using the other control groups. Patients with serum calcium levels higher than 9.6 mg/dL and a PTH index lower than 0.315 are likely to be affected by HCINF1. Their diagnosis may be confirmed using MS and genetic analysis.
Identifiants
pubmed: 38329607
doi: 10.1007/s40618-024-02312-7
pii: 10.1007/s40618-024-02312-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Jones G, Prosser DE, Kaufmann M (2012) 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 523(1):9–18
doi: 10.1016/j.abb.2011.11.003
pubmed: 22100522
Jones G, Prosser DE, Kaufmann M (2014) Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55(1):13–31
doi: 10.1194/jlr.R031534
pubmed: 23564710
pmcid: 3927478
Jones G, Kottler ML, Schlingmann KP (2017) Genetic diseases of vitamin D metabolizing enzymes. Endocrinol Metab Clin N Am 46(4):1095–1117
doi: 10.1016/j.ecl.2017.07.011
Cappellani D, Brancatella A, Kaufmann M, Minucci A, Vignali E, Canale D, De Paolis E, Capoluongo E, Cetani F, Jones G et al (2019) Hereditary hypercalcemia caused by a homozygous pathogenic variant in the CYP24A1 Gene: a case report and review of the literature. Case reports in endocrinolo. https://doi.org/10.1155/2019/4982621
doi: 10.1155/2019/4982621
Schlingmann KP, Ruminska J, Kaufmann M, Dursun I, Patti M, Kranz B, Pronicka E, Ciara E, Akcay T, Bulus D et al (2016) Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J Am Soc Nephrol 27(2):604–614
doi: 10.1681/ASN.2014101025
pubmed: 26047794
Fencl F, Blahova K, Schlingmann KP, Konrad M, Seeman T (2013) Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr 172(1):45–49
doi: 10.1007/s00431-012-1818-1
pubmed: 23001465
Cools M, Goemaere S, Baetens D, Raes A, Desloovere A, Kaufman JM, De Schepper J, Jans I, Vanderschueren D, Billen J et al (2015) Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study. Bone 81:89–96
doi: 10.1016/j.bone.2015.06.018
pubmed: 26117226
Jobst-Schwan T, Pannes A, Schlingmann KP, Eckardt K-U, Beck BB, Wiesener MS (2015) Discordant clinical course of vitamin-D-Hydroxylase (CYP24A1) associated hypercalcemia in two adult brothers with nephrocalcinosis. Kidney Blood Press Res 40(5):443–451
doi: 10.1159/000368520
pubmed: 26304832
Carpenter TO (2017) CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. J Steroid Biochem Mol Biol 173:337–340
doi: 10.1016/j.jsbmb.2017.01.006
pubmed: 28093352
Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H et al (2011) Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365(5):410–421
doi: 10.1056/NEJMoa1103864
pubmed: 21675912
Brancatella A, Cappellani D, Kaufmann M, Borsari S, Piaggi P, Baldinotti F, Caligo MA, Jones G, Marcocci C, Cetani F (2021) Do the heterozygous carriers of a CYP24A1 mutation display a different biochemical phenotype than wild types? J Clin Endocrinol Metab 106(3):708–717
doi: 10.1210/clinem/dgaa876
pubmed: 33249478
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Brancatella A, Cappellani D, Kaufmann M, Semeraro A, Borsari S, Sardella C, Baldinotti F, Caligo MA, Jones G, Marcocci C et al (2022) Long-term Efficacy and safety of rifampin in the treatment of a patient carrying a CYP24A1 loss-of-function variant. J Clin Endocrinol Metab 107(8):e3159–e3166
doi: 10.1210/clinem/dgac315
pubmed: 35569070
Cappellani D, Brancatella A, Morganti R, Borsari S, Baldinotti F, Caligo MA, Kaufmann M, Jones G, Marcocci C, Cetani F (2022) Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review. Eur J Endocrinol. https://doi.org/10.1530/EJE-21-0713
doi: 10.1530/EJE-21-0713
Kaufmann M, Schlingmann K-P, Berezin L, Molin A, Sheftel J, Vig M, Gallagher JC, Nagata A, Masoud SS, Sakamoto R et al (2021) Differential diagnosis of vitamin D-related hypercalcemia using serum vitamin D metabolite profiling. J bone Miner Res Off J Am Soc Bone Miner Res 36(7):1340–1350
doi: 10.1002/jbmr.4306
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930
doi: 10.1210/jc.2011-0385
pubmed: 21646368
El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT (2023) Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 108(3):507–528
doi: 10.1210/clinem/dgac621
pubmed: 36545746
Hu MI (2021) Hypercalcemia of malignancy. Endocrinol Metab Clin N Am 50(4):721–728
doi: 10.1016/j.ecl.2021.07.003
Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, Foreman JW, Chelminski PR, Kumar R (2012) Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 97(3):E423–E427
doi: 10.1210/jc.2011-1935
pubmed: 22337913
pmcid: 3319216